Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CODAK: A Retrospective Observational Research Study to Describe the Characteristics and Real-world Clinical Outcomes of Patients With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer Receiving Durvalumab in the UK.

NCT04667312 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04667312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04667312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CODAK: A Retrospective Observational Research Study to Describe the Characteristics and Real-world Clinical Outcomes of Patients With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer Receiving Durvalumab in the UK.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 24, 2021
Completion date
September 28, 2022
Enrollment
115 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer nsclc